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Abstract
In contrast with common human infections for which vaccine efficacy can be evaluated directly in field studies, alternative
strategies are needed to evaluate efficacy for slowly developing or sporadic diseases like tularemia. For diseases such as
these caused by intracellular bacteria, serological measures of antibodies are generally not predictive. Here, we used
vaccines varying in efficacy to explore development of clinically useful correlates of protection for intracellular bacteria,
using Francisella tularensis as an experimental model. F. tularensis is an intracellular bacterium classified as Category A
bioterrorism agent which causes tularemia. The primary vaccine candidate in the U.S., called Live Vaccine Strain (LVS), has
been the subject of ongoing clinical studies; however, safety and efficacy are not well established, and LVS is not licensed by
the U.S. FDA. Using a mouse model, we compared the in vivo efficacy of a panel of qualitatively different Francisella vaccine
candidates, the in vitro functional activity of immune lymphocytes derived from vaccinated mice, and relative gene
expression in immune lymphocytes. Integrated analyses showed that the hierarchy of protection in vivo engendered by
qualitatively different vaccines was reflected by the degree of lymphocytes’ in vitro activity in controlling the
intramacrophage growth of Francisella. Thus, this assay may be a functional correlate. Further, the strength of protection
was significantly related to the degree of up-regulation of expression of a panel of genes in cells recovered from the assay.
These included IFN-c, IL-6, IL-12Rb2, T-bet, SOCS-1, and IL-18bp. Taken together, the results indicate that an in vitro assay
that detects control of bacterial growth, and/or a selected panel of mediators, may ultimately be developed to predict the
outcome of vaccine efficacy and to complement clinical trials. The overall approach may be applicable to intracellular
pathogens in general.
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Introduction
Most vaccines against infectious diseases in clinical use today act
by stimulating the production of antibodies, which block virus entry,
neutralize toxins, or otherwise limit infection through a variety of
mechanisms. Measurements of serum antibodies have therefore
been applied to predict successful vaccine-induced protection
against diseases such as rabies, tetanus, and diphtheria [1]. In
contrast, cell-based immune responses provided by T lymphocytes
may be more important for control of intracellular pathogens. To
date,however,no predictivecorrelateshavebeenestablished for any
intracellular pathogen. Understanding T cell effector functions that
control intracellular infections, and developing clinically useful
predictive correlates, would greatly facilitate evaluation of new
vaccines for intracellular pathogens of major public health
importancesuchasMycobacteria,Chlamydia,Salmonella,an dLeishmania.
To address these questions, we have exploited experimental
infection models that use the Live Vaccine Strain (LVS) of
Francisella tularensis, a Gram-negative intracellular bacterium that
causes tularemia. Although the incidence of tularemia in the U.S.
is low, F. tularensis is a bioterrorism concern due to its high
infectivity and mortality rates following pulmonary infection [2].
Antibiotics are effective, but difficulties with diagnosis and with
prompt treatment make developing vaccines a priority [3,4].
However, the sporadic nature of disease likely means that vaccine
field trials for efficacy are impractical.
The use of live attenuated Type B Francisella strains as vaccines
in the former U.S.S.R. during and after World War II had clear
impact on the epidemiology of disease [5]. Successful vaccination
of humans using attenuated bacteria has been mimicked
experimentally; rabbits, guinea pigs, rats, and mice are all either
natural hosts or are susceptible to Francisella, and provide
reasonable animal models for vaccination studies [6]. LVS, an
attenuated strain derived from F. tularensis subsp. holarctica (Type
B) [7], is the only vaccine against tularemia currently undergoing
clinical development in the U.S. [2,4]. Human challenge studies,
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vaccination provides at least partial protection against some forms
of the disease, but specific efficacy levels have not been firmly
established [2–5,8–10]. In contrast, observations suggested
minimal protection of people following vaccination with killed
Francisella despite stimulating production of abundant serum
antibodies [3,8,11–12], similar to experimental studies using mice
[13–16], especially following aerosol exposure to the most virulent
strains.
Examination of broth cultures of all strains of F. tularensis,
including LVS, on blood agar plates reveals a variety of colony
morphologies. These opacity variants suggest bacterial phase
variation, a phenotype that may confound evaluation and use of
LVS. Lots of LVS that include a high proportion of phase variants
have been associated with reduced immunogenicity in humans
[4,17], as suggested earlier in animal studies [7]. Stable opacity
variants of LVS, denoted LVS-G and LVS-R, have been isolated
in vitro [18]. These isolates express alternative chemotypes of
Francisella LPS, and appear to be analogous to clinical lots with
reduced immunogenicity in humans. However, LVS-G and LVS-
R have not been tested as vaccines in any experimental models,
including mice, to date.
Murine infections with LVS provide a well-established model of
infection and immunity against Francisella, and indeed for
intracellular bacteria generally [19–21]. Similar to many intracel-
lular bacteria, LVS infects and replicates primarily in macrophag-
es [22], but exhibits convenient route-dependent virulence in mice
[19]. Thus, LVS administered to mice subcutaneously or
intradermally (ID) has a high LD50 of about 10
6 and establishes
a vaccinating infection, eliciting strong cellular as well as humoral
immune responses. However, doses of 10
1 or more of LVS
administered to mice intraperitoneally (IP) or intravenously are
lethal. BALB/c or C57BL/6 mice vaccinated ID with 10
4 LVS
survive lethal challenge with LVS of up to 10
6 IP, and are at least
partially protected against parenteral challenge with fully virulent
Type A F. tularensis SchuS4 [3,23–24]. Also similar to many
intracellular pathogens, in vivo studies clearly demonstrate that this
protection is dependent on T lymphocytes, and involves
production of Interferon gamma (IFN-c), Tumor Necrosis Factor
alpha (TNF-a), and nitric oxide (NO). To further uncover T cell
effector mechanisms, we have previously developed an in vitro
tissue culture system to mimic in vivo immune responses [25–26], in
which LVS-immune lymphocytes are co-cultured with LVS-
infected bone marrow derived macrophages and intramacrophage
bacterial replication is measured. LVS-immune splenocytes, liver
leukocytes, and lung leukocytes all control intramacrophage LVS
replication in vitro, but naive cells do not [27]. In this assay,
appropriate T cell subpopulations but not B cells or myeloid cells
have activity, and the model appears to faithfully reflect known in
vivo T cell effector mechanisms [25–26].
Here, we take advantage of a panel of Francisella vaccine
candidates, including LVS, LVS-G, LVS-R, and heat-killed LVS,
that induced quantitatively different levels of protection in mice
against Francisella challenge. These vaccines were chosen to
approximate Francisella vaccines studied in humans; thus, LVS
has been associated with reasonable efficacy, while lots of LVS
with higher proportions of opacity variants exhibit reduced
immunogenicity (modeled here by the stable variants LVS-G
and LVS-R), and killed Francisella provided poor protection in
humans. Using this panel, we searched for immune responses that
predict successful protection. We found that the relative activity of
Francisella-immune lymphocytes in vitro in the co-culture assay, as
well as the relative expression of a group of immunologically-
related genes in cells recovered from this assay, correlated with the
degree of protection observed in vivo. This approach to identifying
correlates, which couples a functional in vitro assay that detects
reduction in intracellular bacterial loads with expression of
relevant mediators, may be generally applicable to vaccine-
induced protection against intracellular pathogens.
Materials and Methods
Ethics statement
These studies carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
experiments performed using LVS only were conducted under
protocols approved by the Animal Care and Use Committee
(ACUC) of CBER. Experiments including F. tularensis SchuS4
challenge were performed at the Rocky Mountain Laboratories
(RML) under protocols approved by the RML ACUC. Both sets of
protocols stressed practices and procedures designed to strictly
minimize any suffering.
Experimental animals
Six to twelve week old wild type male C57BL/6J mice were
purchased from Jackson Laboratories (Bar Harbor, ME). All mice
were housed in sterile microisolator cages in a barrier environment
at CBER/FDA, fed autoclaved food and water ad libitum, and
routinely tested for common murine pathogens by a diagnostic
service provided by the Division of Veterinary Services, CBER.
Within an experiment, all mice were age matched.
Bacteria and growth conditions
F. tularensis strain SchuS4, provided by Jeannine Peterson,
(Centers for Disease Control, Fort Collins, CO); F. tularensis LVS
(American Type Culture Collection 29684); F. tularensis LVS-G
and LVS-R, originally obtained from Francis Nano (University of
Victoria, Victoria, British Columbia, CA); and Listeria monocytogenes
strain EGD (ATCC 15313) were all grown to mid-log phase in
modified Mueller-Hinton (MH) broth (Difco Laboratories, De-
troit, MI), as previously described [28], harvested, and frozen in
Author Summary
Diseases such as tuberculosis (caused by Mycobacterium
tuberculosis) or tularemia (caused by Francisella tularensis)
result from infections by microbes that live within cells of a
person’s body. New vaccines are being developed against
such intracellular pathogens, but some will be difficult to
test, because disease takes a long time to develop (e.g.,
tuberculosis) or because outbreaks are unpredictable (e.g.,
tularemia). Usually such infections are controlled by
activities of T cells. However, there are no accepted
measures of T cell function that reliably predict vaccine-
induced protection. We studied two new ways to do so.
We used a group of vaccine candidates against tularemia
that stimulated good, fair, or poor protection of mice
against Francisella challenge. We then measured whether
Francisella–immune cells from vaccinated mice controlled
the growth of bacteria inside cells, and/or whether the
expression of immune genes in Francisella–immune cells
was increased. We found that the degree of protection was
matched by the degree of the cells’ function in controlling
intramacrophage bacterial growth. Further, the degree
was predicted by relative amounts of gene expression for
several immune mediators. Thus the two new options
explored here may help predict protection, without
waiting for the onset of disease.
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separate experiments determined numbers of live colony forming
units (CFU), confirmed typical colony morphologies, and con-
firmed expected LD50s and times to death using adult male
BALB/cByJ mice (which are the most sensitive strain for quality
control testing). Bacteria were periodically thawed for use, and
viability was quantified by plating serial dilution on modified MH
agar plates. Aliquots of F. tularensis LVS were heat killed at 56uC
for 30 minutes immediately prior to use, and complete killing
confirmed by plate count.
Bacterial immunizations and challenge
Groups of mice were immunized by intradermal (ID) injection
with 1610
4 CFU LVS, 1610
4 LVS-G, 1610
4 LVS-R, or an
amount equivalent to 1610
8 heat-killed LVS; doses of each were
optimized in initial experiments for maximal protection against
lethal IP LVS challenge. All vaccines were diluted in 0.1 ml
phosphate-buffered saline (PBS) (BioWhittaker, Walkersville, MD)
containing ,0.01 ng of endotoxin/ml. Actual doses of inoculated
bacteria were retrospectively determined by plate count; control
groups received 0.1 ml PBS ID. As indicated, four – twelve weeks
after vaccination, mice were challenged with 10
3 –1 0
6 LVS
intraperitoneally (IP), or 50 CFU SchuS4 subcutaneously (SC),
and monitored for survival. Animals were euthanized when clearly
moribund.
Preparation of splenocytes
Single-cell suspensions of splenocytes were generated for in vitro
culture, flow cytometry, and qRT-PCR analysis by standard
techniques, and had no detectable CFU at the time of harvest.
Viability was assessed by exclusion of trypan blue and flow
cytometry (see below).
Infection of bone marrow–derived macrophages with F.
tularensis LVS and co-culture with splenocytes
Co-cultures were performed in 24 well tissue culture plates as
described previously [25–27,29–31]. Briefly, bone marrow mac-
rophages (BMMØ) were cultured in complete DMEM (DMEM
supplemented with 10% heat-inactivated FCS [HyClone, Logan,
UT], 10% L-929-conditioned medium, 0.2 mM L-glutamine,
10 mM HEPES buffer, and 0.1 mM nonessential amino acids) in
24 well plates. Confluent adherent macrophage monolayers were
infected for 2 hours with F. tularensis LVS at a multiplicity of
infection (MOI) of 1:20 (bacterium-to-BMMØ), washed, treated
for 60 min with 50 mg/ml gentamicin, and washed extensively
with antibiotic-free medium. Single-cell suspensions of splenic
lymphocytes derived from vaccinated mice (5610
6/well, or as
indicated) were added to confluent LVS-infected macrophages
(,1610
7/well) [25–26]. At the indicated time points, non-
adherent cells were harvested, centrifuged and assessed for
changes in cell surface phenotype by flow cytometry or gene
expression by qRT-PCR as described below. Supernatants from
harvested cells was collected and stored at 270uC until analyzed
for nitric oxide and cytokines as described below. Intracellular
bacterial loads in adherent macrophages were determined as
previously described. Additional macrophages were collected
following incubation in 0.05% trypsin/EDTA for 5 minutes,
followed by neutralization with complete media containing serum.
Real time PCR
Cells to be assessed for changes in gene expression by qRT-
PCR were pelleted by centrifugation for 10 minutes at 1000 rpm,
immediately immersed in RNAlater (Ambion, Austin, TX) and
stored at 270uC until further characterization. Total RNA was
extracted from samples using RNeasy mini kits (Qiagen, Valencia,
CA), according to the manufacturer’s directions. RNA quality and
concentration were assessed by Bioanalyzer, including calculation
of the RNA Integrity Number (RIN) via a software algorithm that
estimates RNA sample integrity from elements in the bioanalyzer
electrophoretic trace, and then assigns a score to RNA quality
between 0 and 10 (Agilent Technologies, Santa Clara, CA). One
microgram of RNA was used to synthesize cDNA using the
commercially available kit RetroScript Reverse Transcription for
RT-PCR (Ambion, Applied Biosystems Foster City, CA),
following the manufacturer’s instructions. Semi-quantitative real-
time PCR amplification was completed with an ABI Prism 7000
sequence detection system (Applied Biosystems, Carlsbad, CA).
For initial screening of genes’ expression, cDNA prepared from
non-adherent cells was diluted and used to amplify a panel of
genes of immunological interest (e.g., Th1-Th2-Th3 RT
2 Profiler
PCR Array System, SABiosciences, Frederick, MD), following the
manufacturer’s instructions. To validate the initial array qRT-
PCR results, a second series of independent amplifications for
selected genes were performed. Independent primers and probes
were purchased from Applied Biosystems. cDNA was initially
diluted to 100 ml and then two ml of each cDNA was further
diluted to a volume of 25 ml PCR mix (Applied Biosystems)
containing 0.1 mM and 0.2 mM of each primer and probes,
respectively. Serial dilutions of each individual gene were used to
generate a Glyceraldehyde phosphate dehydrogenase (GAPDH)
standard curve. For PCR amplifications, the initial denaturation at
95uC for 10 minutes were followed by 40 cycles of 95uC for 15
seconds and 60uC for 1 minute. The level of mRNA of each gene
relative to the GAPDH mRNA concentrations was calculated by
plotting the crossing point (Ct) of each amplification in relationship
to the GAPDH standard curve. Delta Ct (DCt), and the ratio
between DCt of vaccines’ samples and control samples (DDCt),
were then calculated.
Flow cytometry
Single cell suspensions prepared from spleens and splenocytes
recovered from co-culture after the indicated time of culture were
stained for a panel of murine cell surface markers and subjected to
multiparameter analyses using a Becton-Dickinson LSR II flow
cytometer (San Jose, CA) and FlowJo (Tree Star, Inc) software
essentially as previously described [29–30]. Briefly, cells were
washed and resuspended in flow cytometry buffer (PBS/2%
serum), and non-specific binding of antibodies was inhibited by
blocking Fc receptors with anti-CD16 (Fc Block; BD Pharmingen).
To discriminate live from dead cells, a staining step for dead cells
was performed using a commercially available kit and following
manufacturers’ instruction (Live/Dead Staining Kit, Invitrogen).
The cells were then washed and stained for cell surface markers.
Antibody concentrations were optimized separately for use in
seven- to nine-color staining protocols as required, using
appropriate fluorochrome-labeled isotype matched control anti-
bodies. The following antibodies were used: anti-B220 (clone RA3-
6B2), anti-CD19 (clone 1D3), anti-TCRb (clone H57-597), anti-
CD4 (clone RM4-5), anti-CD8b (H35-17.2), anti-NK1.1 (clone
PK136), anti-CD11b (clone M1/70), anti-Gr-1 (clone RB6-8C5),
and anti-CD11c (cloneHL3), each labeled with a variety of
fluorochromes as needed (above antibodies were purchased from
BD Pharmingen).
Statistical analyses
Kaplan Meier curves were plotted to compare time to death
following lethal LVS challenge between different vaccine
Protective Correlates for Intracellular Bacteria
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compare survival of different groups (using Prism, GraphPad
Software, La Jolla, CA). Linear regression models were fit to
compare the effects of splenocytes on controlling bacterial
growth from different vaccine groups while adjusting for
splenocyte concentration. Univariate and multivariate logistic
regressions were used to correlate protection against lethal LVS
challenge with either fold change in gene expression at two
different time points (,6 weeks after vaccination and ,12
weeks after vaccination), or with all data combined across both
time point using standardized scores of gene expression. The
results of these analyses were quite similar, and thus the results
using all data combined are shown here. Standardized scores
were used to protect against the possibility that the relative
magnitude of gene expression for any given gene might be
relatively different at the early time point compared to the late
time point. Standardized scores were obtained by subtracting
the average log expression level and then dividing by the
standard deviation of the log expression level in the same
experiment. The Akaike information Criterion was used to
compare different logistic regression models. Pearson’s correla-
tion coefficients of standardized scores of expression level for
pairs of genes were reported. All p-values were two-sided, and p-
values,0.05 were considered to be statistically significant. Data
analyses were conducted using R (R Foundation for Statistical
Computing, Vienna, Austria).
Optimization of conditions for analyses
Initial studies optimized conditions for these experiments;
further characterization and modifications of previously published
in vitro co-culture methodologies [25–26] were required to be most
appropriate for the present purposes. Detailed information
regarding data supporting the resulting modifications is provided
in Supporting Information (see Supporting Information, Text S1,
Figures S1–S3, and Table S1).
Results
Determination of the ability of in vitro co-cultures to
reflect the hierarchy of protection stimulated by
qualitatively different Francisella vaccines
To determine whether the in vitro co-culture system may serve as
a functional correlate of protection, we first identified a panel of
vaccine candidates that provided different degrees of protection
against lethal Francisella challenge in vivo. C57BL/6J mice were
vaccinated ID with 10
4 LVS, with 10
4 of the opacity variants LVS-
G or LVS-R, or with 10
8 -heat killed (HK-) LVS, and then
challenged one month after vaccination with increasing lethal
doses of LVS IP (Figure 1). All mice vaccinated with wild type
LVS survived challenge with up to 5610
5 LVS IP, and 75%
survived challenge with the highest dose tested, 10
6 LVS IP. In
contrast, mice vaccinated with LVS-G exhibited 90% survival
following challenge with 5610
5 CFU and 30% following chal-
Figure 1. Hierarchy of strength of protection against lethal systemic F. tularensis LVS challenge after vaccination of mice with LVS or
the variants LVS-G, LVS-R, and heat-killed LVS. C57BL/6J mice were immunized by ID infection with 1610
4 CFU LVS, 1610
8 HK-LVS, 1610
4
LVS-G, or 1610
4 LVS-R. At 6 weeks after vaccination, mice vaccinated with PBS were challenged with 10
3 or 10
4 LVS IP; mice vaccinated with HK-LVS
were challenged with 10
3,1 0
4, or10
5 LVS IP; and mice vaccinated with LVS, LVS-G, and LVS-R were challenged with 5610
4,1 0
5,5 610
5,o r1 0
6 LVS IP,
as indicated for each group, and monitored for survival. Results shown are from one representative experiment of three independent experiments of
similar design with similar outcome.
doi:10.1371/journal.ppat.1002494.g001
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6 CFU. Mice vaccinated with LVS-R exhibited
only 20% survival following challenge with 5610
5 CFU, and none
survived challenge with 10
6 CFU. Finally, vaccination with HK-
LVS failed to protect against challenge with 5610
4 CFU or
higher. In later experiments, a single challenge dose of 5610
5 -1 0
6
LVS IP was chosen as appropriate for discriminating between the
degree of protection provided by all vaccines in the panel.
These data indicated that this panel of candidate vaccines
exhibited a hierarchy of relative protection against in vivo lethal LVS
challenge, such that LVS.LVS-G.LVS-R.HK-LVS.PBS (na-
ive control). We next examined the protective capacity of these
vaccines against lethal parenteral challenge with a selected dose of
fully virulent Type A F. tularensis (SchuS4). Similar to the outcome
using LVS challenge, and consistent with previous reports [32],
approximately 30% of mice vaccinated with LVS survived this dose
of SchuS4 challenge and time to death of those that died was greatly
extended, while vaccination with LVS-G protected only 10% of
mice against lethal SchuS4 challenge (Figure 2). In contrast to
challenge with LVS, vaccination with LVS-R did not provide
detectable protection against this dose of SchuS4 challenge, and
vaccination with HK-LVS only slightly extended time to death.
Nonetheless, for this group of vaccines, a similar hierarchy of
protective efficacy found following challenge with wild type LVS
was also found using challenge with fully virulent Francisella.
In parallel with in vivo vaccination and challenge studies, the
activities of splenocytes obtained from mice vaccinated with LVS,
LVS-G, LVS-R, HK-LVS, or PBS (control) were compared. To
determine the relative effectiveness of each type of primed cells,
decreasingnumbersofsplenocyteswereadded toa constantnumber
of LVS-infected macrophages. As seen in Figure 3A, on a per-cell
basis, cells obtained from LVS-infected mice were most effective in
controlling the intramacrophage growth of LVS; those from LVS-G
vaccinated mice were less effective, and those from LVS-R-
vaccinated micethe leasteffective. The relationship between relative
control by cells from the different groups was then investigated. A
linear regression with indicators of different vaccine groups and the
cell concentration as covariates was used to compare log CFU of
recovered bacteria in different vaccine groups, adjusting for the
levels of cell concentrations (Figure S4). The result of regression
analysis demonstrated that, for any fixed cell concentration, cells
from LVS-G-vaccinated mice were significantly less effective in
controlling bacteria growth, a difference of about 0.95 log,
compared to those from LVS-vaccinated mice (p,0.001). Similarly,
cells from LVS-R-vaccinated mice were about 1.57 log less effective
than cells from LVS-vaccinated mice (p,0.001). Finally, cells from
LVS-R-vaccinated mice were 0.62 logs less effective than from those
from LVS-G-vaccinated mice (p,0.001). As seen previously [25–
27,29–31], the results suggested that co-cultures containing cells
from naive mice exhibited minimal and inconsistent reductions in
bacterial numbers compared to those with LVS-infected macro-
phages alone (e.g., Figure 3A, p=0.02; Figure 3B, p=0.35);further,
there was no significant relationship between the concentration of
naive cells and bacterial numbers. Finally, cells obtained from mice
vaccinated with HK-LVS did not significantly inhibit bacterial
growth control compared to either naive cells or cultures with LVS-
infected macrophages only, even at the highest cell numbers tested
(Figure 3B). Thus, the hierarchy of in vitro activities of cells from
vaccinated mice was again LVS.LVS-G.LVS-R.HK-LVS.
Further, because only LVS-immune T cells are active in this setting,
these data estimate the relative frequencies of memory T cells.
Supernatants and cells were also recovered on day 2 from each
type of co-culture. Supernatants were then analyzed as above for
cytokine production by ELISA and NO production by Griess
reaction; cells were characterized by flow cytometry; and mRNA
prepared from recovered cells was analyzed for relative gene
expression. The amounts of TNF-a, IFN-c, and NO produced were
consistent with previously published studies using LVS vaccination
alone [25–27,29–31]. Here, relative cytokine and NO production
exhibited the same pattern as that observed in the survival studies
and in in vitro control of intramacrophage LVSreplication, such that
LVS.LVS-G.LVS-R.HK-LVS and naive groups (data not
shown). Flow cytometry analyses of recovered cells confirmed the
relative enrichment of T cells (similarto that illustrated in Table S1),
and did not reveal any obvious differences between vaccine groups
(data not shown). Collectively, these data indicated that the
hierarchy of protective capacity engendered by in vivo vaccination
with this panel of vaccines was faithfully reflected by the relative
ability of each type of Francisella-immune splenocytes to persist in
culture, produce relevant cytokines and nitric oxide, and ultimately
to effect control of intramacrophage bacterial growth.
Identification of genes whose relative expression
following in vitro co-culture reflects the hierarchy of
protection stimulated by qualitatively different
Francisella vaccines
Because these in vitro co-culture conditions reliably detected
differences in vaccine quality, non-adherent immune splenocytes
Figure 2. Hierarchy of survival against lethal systemic F.
tularensis SchuS4 challenge after vaccination of mice with LVS
or the variants LVS-G, LVS-R, and heat-killed LVS. Groups of five
C57BL/6J mice were immunized by ID infection with 1610
4 CFU LVS,
1610
4 LVS-G, 1610
4 LVS-R, or 1610
8 HK-LVS. At 4 weeks after
vaccination, all mice were challenged with 50 CFU SchuS4 subcutane-
ously (SC), and monitored for survival; all mice that survived through
day 20 were long term survivors. The combined results of two
independent experiments, using 10 total mice per vaccine group, are
shown. By log-rank (Mantel-Cox) analysis, vaccination with LVS and LVS-
G significantly improved survival (both p,0.0001 compared to naive
mice), and were significantly different from each other (p=0.0041);
vaccination with HK-LVS or LVS-R did not significantly improved survival
compared to naive mice (p=0.0968 or p=0.3425, respectively), but
both of these were significantly different compared to vaccination with
LVS or LVS-G (p,0.0001 for all combinations).
doi:10.1371/journal.ppat.1002494.g002
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and then analyzed in detail for relative gene expression. For these
experiments, groups of mice were vaccinated with LVS, LVS-G,
LVS-R and HK-LVS. At either 6 weeks or 12 weeks after
vaccination, some mice were challenged in vivo, and other mice
were sacrificed at the same time to prepare splenocytes, perform in
vitro co-cultures, and recover non-adherent cells for mRNA
analyses. Similar to initial studies using cells from naive or LVS-
vaccinated mice only (see Supporting Information text), the
relative mRNA expression of genes of immunologic interest in
splenocytes from mice vaccinated with LVS, LVS-G, LVS-R, or
HK-LVS was compared to that of splenocytes from naive mice by
RT-PCR, using commercially available arrays that included
immunologically-related genes (e.g., Profiler PCR Th1-Th2-Th3
array). Data generated from initial experiments using the complete
vaccine panel revealed that some genes, such as GF1 and CCR4,
which in initial studies were up-regulated in LVS-primed cells
compared to naive cells, were either inconsistent or up-regulated
to a similar degree for all vaccines and did not exhibit a differential
pattern (Table S2, ‘‘SYBR’’). In contrast, other genes appeared to
exhibit a range of expression that reflected the relative
effectiveness of vaccination. For example, IFN-c appeared to be
highly expressed in LVS-primed cells as well as in cells from LVS-
G-vaccinated mice, only moderately expressed in cells from LVS-
R-vaccinated mice, and expressed very little in cells from HK-
LVS-vaccinated (all compared to naive mice). Similar to IFN-c,
the relative expression of several other genes, such as IL-6, TNF-a,
IL-18bp, and GM-CSF, reflected the relative level of both in vivo
protection and in vitro bacterial growth control activities of the
different vaccines.
The initial comparisons focused attention on a group of 15
genes with apparently differential expression patterns, either in
terms of relative up-regulation or relative down-regulation. Seven
other genes were also considered of ongoing interest, either
because they were not included on the commercial panel used and
had a known biological relationship to other genes that were
correlated with protection (e.g., IL-22), and/or because results
were ambiguous (e.g., IL-17A and IL-13). A set of 22 genes were
therefore selected for more detailed studies, and separate primer-
probe sets prepared to perform qRT-PCR analyses. This
approach was applied to again analyze mRNA from previous
experiments, as well as mRNA from additional independent
experiments. Collectively, these included two independent exper-
iments using splenocytes from mice vaccinated six weeks earlier
(Table S2, experiments 4 and 6) and two independent experiments
using mice vaccinated twelve weeks earlier (Table S2, experiments
5 and 7). For analysis of qRT-PCR data from selected genes, Ct
results were normalized to a standard curve of GAPDH before
calculation of DCt and fold changes (DDCt) between samples from
naive and vaccinated mice (DDCt). When compared for up-
regulated genes, the fold change for most of these genes in cells
from LVS-vaccinated mice was similar to those in cells from LVS-
G-vaccinated mice; both were greater than those in cells from
LVS-R vaccinated mice, which in turn were greater than those in
cells from HK-LVS vaccinated mice or naive mice (Figure 4,
panels A–C). In contrast, when the relative fold change (DDCt) of
putatively down-regulated genes was compared across different
experiments, the amounts of differences were relatively modest
(Figure 4, panel D), similar to observations made using Profiler
PCR arrays. Taken together, using a different detection system
(including probes instead of SYBR Green) and a different
normalization approach, we again found clear relationships
between the relative expression levels of most members of this
panel of up-regulated genes and the hierarchy of vaccine
protection. Further, the latter method allowed more accurate
quantification of relative gene expression.
Specificity of relative gene expression following in vitro
co-culture
To examine whether gene expression patterns observed are
specific for F. tularensis LVS vaccination and related to Francisella
vaccine efficacy, C57BL/6J mice were vaccinated ID with LVS,
LVS-R, HK-LVS, or 5610
3 Listeria monocytogenes. Two weeks later,
mice were either challenged with lethal dose of 10
6 LVS IP, or
used to prepare spleen cells that were co-cultured with LVS-
infected macrophages, recovered after two days, and analyzed for
relative gene expression. For the LVS related vaccines, the same
patterns of survival and in vitro growth control were found (data not
shown). In contrast, Listeria-vaccinated splenocytes did not
significantly reduce the intramacrophage growth of LVS com-
pared to control co-cultures (data not shown; and see [25]), and
Listeria-vaccinated splenocytes exhibited an absence of up- or
down-regulation. The fold change (DDCt) values using Listeria-
vaccinated splenocytes were mostly similar to those observed in
cells from mice vaccinated with HK-LVS. For example, IFN-c up-
regulation in cells from LVS-vaccinated mice was about 22 fold
compared to naive mice; 7.2 in cells from LVS-R-vaccinated mice;
0.8 in cells from HK-LVS vaccinated mice; and 1.7 in cells from
Listeria-vaccinated mice. Thus, the working panel of genes
specifically reflected activities of Francisella-immune cells.
Integrated statistical analyses of the ability of relative
gene expression following in vitro co-culture to reflect
the hierarchy of protection stimulated by qualitatively
different vaccines
The resulting data derived from both the Profiler arrays and
from the selected genes assessed by qRT-PCR were used to
examine statistical correlations between survival and in vitro gene
expression in response to the different vaccines (see Table S2, all
experiments). For each gene, the proportion of surviving mice was
plotted against a standardized score of gene expression. Examples
of these relationships are illustrated in Figure 5, in which analyses
of IFN-c, TNF-a, IL-6, and T-bet relative mRNA expression by
qRT-PCR are shown; p values for the relationship between
survival and all genes analyzed by Profiler array or qRT-PCR are
Figure 3. Splenocytes from mice vaccinated with a panel of LVS-related vaccines exhibit a hierarchy of control of intramacrophage
LVS growth. (A) BMMØs from C57BL/6J mice were infected with LVS at an MOI of 1:20 (bacterium-to-macrophage ratio; ‘‘Mac alone’’), and co-
cultured with the indicated numbers of splenocytes obtained from either naive C57BL/6J mice or C57BL/6J mice vaccinated 1610
4 CFU LVS, 1610
4
LVS-G, or 1610
4 LVS-R 6 weeks previously. Here, for all co-cultures containing added splenocytes, ‘‘1x’’=5610
6 splenocytes per well (used in all
previous experiments), and 0.5x, 0.25x, and 0.1x refer to corresponding decreases in the total number of added splenocytes. (B) BMMØs from C57BL/
6J mice were infected with LVS at an MOI of 1:20 (bacterium-to-macrophage ratio), and co-cultured with splenocytes obtained from either naive
C57BL/6J mice or C57BL/6J mice vaccinated 1610
4 CFU LVS or 1610
8 HK-LVS 6 weeks previously. For both A and B, after three days of co-culture,
BMMØ were washed, lysed, and plated to determine the recovery of intracellular bacteria. Values shown are the mean numbers of CFU/ml 6 SD of
viable bacteria for triplicate samples. Results shown are from one representative experiment of three (A) or four (B) independent experiments of
similar design with similar outcome.
doi:10.1371/journal.ppat.1002494.g003
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respectively). Of the 22 selected genes, 20 were significantly
related to survival according to Profiler array data, validating the
initial selection, but only 16, were significantly related to survival
using qRT-PCR data.
The logistic regressions analyses using data from the Profiler
arrays (Table S2, SYBR) indicated that about 20 other genes, in
addition to the 22 genes already selected, were also significantly
related to survival. These included genes that were up-regulated
(e.g., SOCS3 and Tmed) and some that were down-regulated (e.g.,
Figure 4. Relationship between relative differences in gene expression and type of vaccine for differentially regulated genes. Data
from all four experiments using the full panel of vaccine candidates (Table S2, experiments 4 – 7) are used to provide a graphic representation of the
relationship between type of vaccine and relative gene expression. All data were normalized in relationship to endogenous GAPDH standard curves,
and values shown are median of the fold differences (DDCt) in relationship to naive cells for each type of vaccine, as indicated. Panel A depicts the
genes designated as Group 1 in Table 1 (all significant, p,0.0001); Panel B depicts the genes designated as Group 2 in Table 1 (all significant,
p,0.0001); Panel C depicts the remaining up-regulated genes not included in Groups 1 or 2 of Table 1 (IL-17A, IL-23a, CCR5, and STAT-1 significant
with p,0.05, but IL-13 not significant; see Table S4 for exact p values); and Panel D depicts down-regulated genes (all non-significant; see Table S4 for
p values). The corresponding legends are shown immediately above or immediately below each panel.
doi:10.1371/journal.ppat.1002494.g004
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even for LVS-immune cells compared to naive cells was relatively
small, ,2 for up-regulated genes and .0.5 for down-regulated
genes. Moreover, the range of differences for these genes across all
vaccines was judged too small to be reliably useful in this context,
and these candidates have not yet been pursued further.
Taken together, the genes that exhibited consistent changes of
useful magnitude across all experiments, as well as significant
pairwise correlations of the relative degree of expression between
all possible pairs of genes (Table S5), included IFN-c, IL-6, IL-
12rb2, T-bet (Tbx21), Socs1, and IL18bp (Table 1, Group 1;
Figure 4, panel A). Genes with notable, but less universal,
associations were GM-CSF, IL-27, TNF-a, IL-27, and Irf1
(Table 1, Group 2; Figure 4, panel B; remaining up-regulated
genes are illustrated in Figure 4, panel C, and down-regulated
genes in Figure 4, panel D).
Finally, to assess whether fold changes in mRNA expression for
different genes would work in concert and better predict survival
than single genes, multivariate logistic regression analyses were
performed. Although specific pairs of genes displayed correlative
degrees of expression, multivariate analyses of gene pairs (Table
S6) did not provide stronger associations with survival than any
one gene alone, based on the Akaike information criterion value.
Likewise, groups of three genes did not provide any statistically
significant improvement in survival prediction than did the models
with one or two genes (data not shown).
Discussion
Currently there are no validated options for predicting
protection against intracellular pathogens. Human clinical field
trials for many intracellular pathogens will be difficult, either
because of the long time to develop disease (i.e., tuberculosis), or
the sporadic nature of disease in nature (i.e., tularemia). A recent
FDA regulation provides an option for evaluating vaccine efficacy
using animal studies under special, well-defined circumstances that
may most likely be applicable to biodefense pathogens [33]; but a
rational means of bridging efficacy between animals and humans
and extrapolating vaccine dose will be critical. Many such issues
could potentially be addressed by derivation of correlates of
protection that can be measured in several species. The word
‘‘correlate’’ has been ascribed a wide variety of definitions [1,34];
here, we use the term to refer to a measurement that detects
relevant biological functions critical for, and statistically related, to
protection against an infectious disease [35].
Historically, efforts to identify and measure relevant serum
antibodies have failed to successfully predict vaccine-induced
protection, particularly for replicating, live attenuated vaccine.
Figure 5. Relationship between gene expression and survival across all vaccines studied at six weeks after vaccination for IFN-c,
TNF-a, IL-6, and T-bet. Data from Table S2, all experiments, were analyzed by logistic regression across all vaccines and all time points as described
in the text. For each individual gene, the plotted results shown depict the percent survival of LVS-challenged mice as a function of the standardized
score of the log10 fold difference in gene expression. All mediators depicted here exhibited a significant positive relationship between the degree of
gene expression and survival (see Table 1 and Table S4).
doi:10.1371/journal.ppat.1002494.g005
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parameter to the degree of protection. Production of IFN-c ex
vivo has been extensively explored, particularly in studies of M.
tuberculosis. However, there are many human clinical and
experimental examples where the relative levels of IFN-c
measured do not reflect the degree of successful vaccination
[36–41]. The collective evidence instead indicates that it is likely
that local availability of IFN-c is necessary, but not sufficient, for
protection. More recently, ‘‘multi-functional T cells’’ that exhibit
the ability to simultaneously produce IFN-c, TNF-a, and IL-2,
have been proposed as vaccine correlates [42–43]. While
promising in the context of mouse models of Leishmania infections
[44] and some studies of tuberculosis vaccines [45–47], in other
cases no obvious correlation has been detected between MFCs and
protection [48–51]. Efforts to develop genomic and metabolomic
biomarker signatures for tuberculosis infection and vaccination,
particularly in the context of HIV/AIDS, are underway [52].
Although still complex, the approach illustrated here of coupling a
panel of qualitatively different vaccines, combined with in vitro re-
stimulation via co-cultures and semi-quantitative mRNA analyses,
clearly identified mediators that correlate strongly with the relative
degree of vaccine-induced protection against lethal challenge in
vivo.
The Francisella infection and immunity model offered the
advantage of having a panel of different vaccine candidates,
coupled with the ability to more precisely define the strength of
protection in vivo by using a range of lethal challenge doses.
Vaccination of humans with LVS engenders production of
Francisella-specific serum antibodies, as well as memory T cells in
peripheral blood that produce IFN-c, IL-17A, and IL-22 following
antigen stimulation [53–56], but these are currently of unknown
contribution to protection of people. To date, there are limited
studies regarding correlates of immunity to Francisella. Vaccination
mice with static Francisella vaccine candidates, including outer
membrane protein preparations or ethanol-inactivated LVS
formulated with Freund’s adjuvant, provided partial protection
against respiratory challenge with 40 CFU of fully virulent type A
F. tularensis, accompanied by production of serum antibodies and
large levels of TNF-a and IL-2 in sera of vaccinated mice after
challenge [57]. In studies using a mouse model to compare
intradermal vaccination of mice with LVS to vaccination with
genetically attenuated mutants of SchuS4, protection against
challenge with fully virulent F. tularensis was not correlated with
levels of serum IFN-c or IgM/IgG antibodies [58]; only
pulmonary IL-17 quantities after secondary challenge appeared
to track with protection [59]. Here, LVS-G and LVS-R,
spontaneous variants that express alternate LPS chemotypes,
proved to provide intermediate levels of in vivo protection (Figure 1).
Because antibodies to LPS likely play a minor role in protection
against lethal Francisella challenge even in mice [60–61], the
reduced protection is unlikely to be explained completely by
reduced serological responses. More likely, reduced protection is
explained either by reduced persistence and total antigen exposure
in these serum-sensitive variants [18]; or, changes in LPS
expression are a visible marker for simultaneous changes in
expression of other bacterial genes that are important in
protection. Of note, it is likely the mechanisms of protection
provided by the live attenuated strains LVS, LVS-G, and LVS-R
are similar, but the strengths of protection quantitatively different;
we consider this an important feature that is critical to permitting
strong interpretations across different vaccines.
Using this panel, a hierarchy of strength of protection was
evident using Francisella LVS challenge of mice (Figure 1).
Although it was not feasible to perform larger experiments using
graded doses of challenge with fully virulent F. tularensis SchuS4,
the proportion of vaccinated survivors and differences in times to
death following challenge with one selected dose supported a
similar hierarchy (Figure 2). Tangentially, these comparisons also
suggest that lethal parenteral challenge of vaccinated mice with
LVS could serve as an informative screen for vaccine efficacy prior
to testing by challenge with fully virulent Type A F. tularensis.
Using carefully selected conditions, we then compared the relative
activity of splenocytes from differentially vaccinated mice in an in
vitro tissue culture system that measures reduction of intrama-
crophage bacterial numbers by immune T cells, and found that
the relative strength of in vivo protection was clearly reflected by the
relative activity of immune splenocytes in vitro (Figure 3). The
results therefore support the utility of the co-culture assay as both a
relevant functional assay in its own right.
Further, despite multiple attempts to identify strong T cell
antigens involved in murine responses to Francisella and develop
associated reagents [62–64], tools such as tetramers remain
lacking. Studies in mice and humans suggest that host responses
do not involve a classical ‘‘immunodominant’’ protein but are
directed to a large collection of protein antigens [65–67]; thus
although tetramer analyses may no doubt eventually prove helpful,
such approaches may detect only a small fraction of the total anti-
Francisella T cell response. Because only LVS-immune are active in
specifically controlling intramacrophage growth of the homolo-
gous bacteria [25–26], the results presented here validate that the
in vitro co-culture assay is a new, and currently the only available,
approach to establish the relative frequency of Francisella-specific
memory T cells in a mixed population (Figure 3, Figure S4).
The in vitro co-culture assay was previously developed using both
Francisella LVS and M. tuberculosis as a research model to explore
Table 1. Working panel of proposed correlates of protection
for the intracellular bacterium Francisella.
Mediator Fold change (range) compared to naive
*
LVS LVS-G LVS-R HK-LVS
Group 1:
IFN-c 23.8 (13 – 359) 49 (12 – 347) 5.5 (0.8 – 33) 0.5 (0.2 – 1.2)
IL-6 6.8 (2.5 – 8) 4.1 (0.8 – 7) 0.8 (0.5 – 2) 0.5 (0.4 – 1.2)
IL-12rb2 2.8 (1.6 – 4) 2.0 (1.2 – 5) 1.1 (0.7 – 1.8) 0.7 (0.5 – 1.1)
T-bet 3.0 (1.7 – 10) 3.0 (1.9 – 5) 1.5 (0.9 – 3) 1.0 (0.4 – 2)
IL-18bp 3.4 (3.1 – 7) 2.6 (0.7 – 6) 1.4 (1.3 – 1.7) 1.0 (0.4 – 1.7)
SOCS-1 4.1 (2.7 – 15) 7.0 (3 – 17) 3.6 (1.0 – 5) 1.2 (0.8 – 1.6)
Group 2:
GM-CSF 3.8 (0.4 – 10) 3.8 (1.5 – 12) 0.8 (0.4 – 2.3) 0.3 (0.3 – 1.7)
TNF-a 2.5 (1.4 – 3) 1.3 (0.8 – 4) 0.9 (0.7 – 1.8) 1.0 (0.8 – 1.1)
Irf-1 2.2 (1.5 – 4) 2.3 (1.3 – 5) 1.5 (1.8 – 3) 0.5 (0.5 – 1.64
IL-22 2.7 (0.4 – 14) 4.2 (1.1 – 13) 1.2 (0.4 – 3) 0.4 (0.1 – 1.2)
IL-27 4.4 (2.2 – 7) 3.3 (0.7 – 8) 1.0 (0.9 – 3) 1.1 (0.5 – 1.7)
CCL7 (MCP-
3)
2.4 (1.9 – 2.6) 1.5 (0.3 – 1.9) 0.6 (0.5 – 0.7) 0.6 (0.3 – 2.0)
*The median fold change of the indicated mediator for each indicated vaccine
group is shown, with the range across all experiments in parenthesis. For the
range in parentheses, fold change values over 2 were rounded to the nearest
whole number, and those less than 2 were rounded to one decimal place.
Results from 4 total experiments were included (see Table S2). p values for
logistic regressions of associations between degree of gene expression and
degree of survival were all,0.001 (see Table S4).
doi:10.1371/journal.ppat.1002494.t001
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and immune T lymphocytes. In many respects, this system
faithfully reflects known in vivo T cell effector mechanisms,
including both IFN-c-dependent and non-IFN-dependent mech-
anisms [25–27,29–31]. However, it should be noted that studies
demonstrated that T cells from LVS-vaccinated IL-12 knockout
mice are quite active in co-cultures, despite the fact that IL-12
knockout mice do not clear a vaccinating LVS infection [31].
Elsewhere, this co-culture approach was recently applied by our
colleagues to murine studies of a panel of vaccine candidates for
M. tuberculosis [68–69]. In those studies, the in vitro assay
successfully discriminated between vaccines with high or moderate
activity, as defined by in vivo protection.
Although we find the in vitro co-culture approach promising, as
well as potentially feasible in the near term, cell-based assays are
difficult to implement for human clinical trials. We therefore
pursued an additional strategy, by searching for genes whose
differential expression was related to the hierarchy of vaccine-
induced in vivo protection and in vitro cellular activity. We focused
on screening immunologically-related genes. This approach is
obviously biased toward analyzing known entities instead of
discovering new ones, but it offered the potential advantage of
identifying relevant mediators. Remarkably, cells recovered from
in vitro culture differentially expressed mediators at the mRNA
level (Figure 4; Figure 5; Table S2) and a number of candidates
emerged (Figure 4; Table 1). Of note, among these mediators,
were IFN-c and TNF-a, as might be expected, and thus validating
the overall approach.
It should be noted that we observed considerable variability in
mRNA levels between experiments. For example, expression of
IFN-c was always highly up-regulated in cells obtained from mice
vaccinated with LVS and LVS-G, but the fold change compared
to naive cells varied between about 13 and 360 (Table 1; Table
S2). We suspect that biological, in addition to technical, reasons
contribute to the observed variability. To increase confidence in
predictors, quantifying a panel of genes is therefore likely to be
preferable over assessing a single gene mediator, even an
important one such as IFN-c. This point may be especially
germane to clinical settings that lack the advantages offered by
using genetically identical inbred mice.
Despite the quantitative variability, from a group of about 84
genes, 16 proved to be robust enough to yield significant
correlations between the magnitude of mRNA expression and
survival, as well as exhibit relatively large differences in the degree
of expression (Figure 5; Table 1; Figure S3; Tables S3 – S6). These
likely include those whose gene products contribute directly to
mechanisms, and those that are co-regulated and only epiphe-
nomena. We are most interested in those that are mechanistically
relevant, and thus likely to serve as definitive predictors across
variables such as time after vaccination, route, dose, tissues
sampled, and especially different animal species. Notably, the most
useful of the expression differences involved up-regulated genes,
which is appealing in potentially reflecting a requirement for
production of a mediator to provide a particular function during
challenge. It is striking that several of the leading candidates are
plausibly related to Th1 cell biology, including T-bet and IFN-c.
Although TNF-a also exhibited significant differential regulation
and is clearly relevant, production of TNF-a is tightly regulated to
avoid toxicity, and thus ex vivo measurements may not be among
the most useful. IL-12rb2 is only found as part of the complete
receptor for IL-12 p70, which is not expressed on resting T cells
but induced by T cell activation and contributes directly to Th1
lineage commitment [70]. For example, in naive transgenic CD4
+
T cells, IFN-c stimulation up-regulates expression of T-bet in a
STAT-1 dependent manner and promotes IL-12Rb2 chain
expression [71]. Notably, STAT-1 was also among our candidate
genes with significant associations, albeit one that exhibited
considerable variability and thus was not included in our two
highest priority groups (Table 1).
In contrast to IFN-c, T-bet, and IL-12rb2, other high priority
candidates such as IL-6, SOCS-1, and IL-18bp were more
surprising. IL-6 has a wide variety of sources and functions, but in
adaptive immunity is most commonly associated with promoting B
cell activation and IgA production and infrequently with resistance
to intracellular pathogens [72]. In the Francisella infection model,
our preliminary results indicate that IL-6 knockout mice are
severely impaired in their ability to survive primary LVS
vaccination (Kurtz and Elkins, manuscript in preparation), as
are T-bet knockout mice and IL-12rb2 knockout mice (Melillo and
Elkins, manuscript in preparation). The specific contribution of
SOCS-1, an important member of a large family of ‘‘suppressor of
cytokine signaling’’ mediators that regulate T cell differentiation as
well as T cell effector functions, awaits further study. Perhaps the
most unexpected candidate is IL-18 binding protein (IL-18bp);
although induced by IFN-c, its production is usually associated
with cells other than leukocytes [73], and to our knowledge has no
reported direct link to Th1 T cell effector functions.
Taken together, the results presented here are in important step
toward the identification of T cell functions and products required
for survival of lethal exposure of intracellular bacteria. We propose
that the candidates described as Group 1 and Group 2 (Table 1)
receive high priority for detailed direct exploration, initially in
animal studies, of biological relevance and mechanistic contribu-
tion. Knowledge obtained by in vitro and pre clinical studies will be
the key to facilitating design of assays with formats amenable to
clinical studies, such as ex vivo re-stimulation of human peripheral
blood leukocytes. It is likely that defining groups of mediators will
be preferable in order to overcome issues related to variability in
measurements, and ensure predictive confidence for human
clinical trials. The larger goal will therefore be to establish
protective levels of each individual mediator, and thus select
combinations that reliably predict successful vaccination against
intracellular pathogens.
Supporting Information
Figure S1 LVS-immune splenocytes control of intrama-
crophage LVS-growth within two days of co-culture.
BMMØs from C57BL/6J mice were infected with LVS at an
MOI of 1:20 (bacterium-to-macrophage ratio), and co-cultured
with splenocytes obtained from either naive C57BL/6J mice
(‘‘Naive,’’ black bars) or C57BL/6J mice infected intradermally
with LVS 6 weeks previously (LVS-immune mice, ‘‘LVS,’’ gray
bars). On the indicated days after infection, BMMØ were washed,
lysed, and plated to determine the recovery of intracellular
bacteria. Values shown are the mean numbers of CFU/ml 6 SD
of viable bacteria for triplicate samples; * indicates values
significantly different between naive and LVS-immune cells
(p=0.0074 for Day 2; p=0.001 for Day 3). Results shown are
from one representative experiment of three independent
experiments of similar design with similar outcome.
(TIF)
Figure S2 Relative gene expression in LVS-immune
splenocytes or LVS-infected macrophages on day two
of co-culture. BMMØs from C57BL/6J mice were either
uninfected (‘‘Mac’’) or infected with LVS at an MOI of 1:20
(bacterium-to-macrophage ratio; ‘‘Mac/LVS’’), and co-cultured
with splenocytes obtained from either naive C57BL/6J mice
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LVS 6 weeks previously (‘‘+Primed spleen’’). After two days of co-
culture, non-adherent splenocytes and adherent infected macro-
phages were recovered from triplicate wells, pooled, mRNA
prepared, and relative expression of IL-6, IFN-c, TNF-a, and IL-
12 p40 (as labeled) and quantitated using specific primer/probe
sets by qRT-PCR. Values shown indicate the relative quantifica-
tion of each gene of interest, as indicated by the panel label.
Results shown are from one representative experiment of four
independent experiments of similar design with similar outcome.
(TIF)
Figure S3 Cytokine secretion during co-culture of LVS-
infected macrophages with LVS-immune splenocytes.
BMMØs from C57BL/6J mice were either uninfected (‘‘Mac’’) or
infected with LVS at an MOI of 1:20 (bacterium-to-macrophage
ratio; ‘‘Mac/LVS’’) and co-cultured with splenocytes obtained
from either naive C57BL/6J mice (‘‘+Naive Splenocytes’’) or
C57BL/6J mice infected intradermally with LVS 6 weeks
previously (‘‘+Primed Splenocytes’’). On the indicated days,
supernatants from triplicate samples (obtained from LVS co-
cultures immediately prior to macrophage lysis) from the indicated
cultures were assessed by ELISA for IL-6 protein, TNF-a, IFN-c,
or IL-12 p40. Values shown are the mean amounts of protein ng/
ml or pg/ml, as indicated, 6 SD for triplicate samples. Results
shown are from one representative experiment of four indepen-
dent experiments of similar design with similar outcome.
(TIF)
Figure S4 Relationship between vaccine-immune cell
concentration and control of intramacrophage bacterial
growth. Data from the experiment depicted in Figure 3 were
analyzed by logistic regression as described, in the text. Results
shown depict log10 recovered bacterial CFU as a function of the
concentration of cells from each vaccinated group added to co-
cultures, where 1 on the X axis corresponds to 5 10
6 splenocytes
per well (see Figure 3A). ----#----, cells from LVS-vaccinated
mice; - - - D - - - cells from LVS-G vaccinated mice; and ----+---,
cells from LVS-R-vaccinated mice. Of note, separate initial
analyses established that the slopes of all interpolated lines were
not significantly different.
(TIF)
Table S1 Changes in proportions of cell subpopulations
over time in culture. BMMØs from wild type C57BL/6J mice
were infected with LVS at an MOI of 1:20 (bacterium-to-
macrophage ratio), and co-cultured with splenocytes obtained
from either naive C57BL/6J mice or C57BL/6J mice infected
intradermally with LVS 6 weeks previously (LVS-immune mice).
On the indicated days after infection, non-adherent cells were
recovered and pooled from triplicate co-cultures, counted under
trypan blue, stained with a panel of fluorescent antibodies to cell
surface markers as well as with a fluorescent viability dye, and
analyzed by multi-parameter flow cytometry.
* The total numbers
of viable cells per well, as assessed by exclusion of trypan blue, are
shown.
{ The proportions of gated cells, as a percent of the total
viable recovered cells, are shown. Results shown are from one
representative experiment of three independent experiments of
similar design with similar outcome.
(DOC)
Table S2 Relative gene expression in splenocytes de-
rived from differentially vaccinated mice. * In each
experiment, 5 mice per vaccine group as well as 5 naive mice
were challenged with 5610
5 -1 0
6 CFU LVS IP (determined by
retrospective plate count), and survival monitored for a month; all
naive mice died within 6 days of challenge, and the numbers of
surviving mice within each vaccine group are shown. { Gene
expression was evaluated by RT PCR using TH1-TH2-TH3
panel (‘‘Profiler’’); selected genes were further evaluated using
specific primer/probe sets (‘‘qRT-PCR’’). ,All values are
calculated fold differences of gene expression between vaccinated
and non-vaccinated (naive) splenocytes. % In experiment 2, the
same mRNA preparation was subjected to two independent PCR
reactions (2a and 2b). # Mice vaccinated in experiments 2, 3, 4
and 6 were challenged, and spleens obtained for overlay and
mRNA analyses, at ,6 weeks after vaccination, and mice
vaccinated in experiments 1, 5 and 7 were analyzed and
challenged ,12 weeks after vaccination. Exps 4 and 5 were
vaccinated at the same time, and Exps 6 and 7 vaccinated at the
same time.
(XLS)
Table S3 Summary of all univariate logistic models
using Profiler array data. The table shows the estimated
coefficient (Coef), standard error (SE), P values (P), and Akaike
information criterion (AIC) for the univariate logistic regression for
each gene. Here, AIC is defined as 2*k-2*Lik, where k is the
number of parameters in a logistic regression model and Lik is log
likelihood. In the case of univariate logistic regression, k=2
(intercept and slope). The p value is a test as to whether relative
expression of the selected gene has any effect on survival (e.g., as
illustrated graphically in Figure 5). Please note that the numbers of
data points available for these gene expression data are different
for different genes (see Table S1, ‘‘Profiler array’’ data). Thus, the
AIC and Lik values of different genes cannot be compared
directly. For example, the univariate model with IL23a as the
covariate yields the smallest AIC and largest log likelihood. The
fitted model, however, is based on only 4 data points in one
experiment (Table S1, Experiment 6).
(DOC)
Table S4 Summary of all univariate logistic models
using qRT-PCR data. Similar to Table S2, this table shows the
estimated coefficient (Coef), standard error (SE), P values (P), and
Akaike information criterion (AIC) for the univariate logistic
regression for each gene. Here, AIC is defined as 2*k-2*Lik, where
k is the number of parameters in a logistic regression model and
Lik is log likelihood. In the case of univariate logistic regression,
k=2 (intercept and slope). The p value is a test as to whether
relative expression of the selected gene has any effect on survival
(e.g., as illustrated graphically in Figure 5). Here, the numbers of
data points available for these gene expression data are the same
for different genes (see Table S1, ‘‘qRT-PCR’’ data), and thus, the
AIC and Lik values of different genes may be compared directly.
(DOC)
Table S5 Pairwise correlation coefficient for all cyto-
kines analyzed by qRT-PCR. Using qRT-PCR data only
(Table S1, ‘‘qRT-PCR’’), this table presents Pearson’s correlation
coefficients of standardized scores of expression level for all
possible pairs of genes. Correlation coefficients greater than 0.8,
suggesting a significant relationship between the relative degrees of
expression of two genes in question, are boldfaced.
(DOC)
Table S6 Logistic regressions for all possible pairs of
genes. Using qRT-PCR data only (Table S1, ‘‘qRT-PCR;’’
univariate results shown in Table S3), this table shows the
estimated coefficient (Coef), standard error (SE), P values (P), and
Akaike information criterion (AIC) for all possible pairs of
predictors as calculated by logistic regression. The p value is a
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have any effect on survival.
(DOC)
Text S1 Optimization of conditions for analyses.
(DOC)
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